[Successful treatment of acute myelomonocytic leukemia developed from essential thrombocythemia with cytarabine plus etoposide].

Abstract

A 77-year-old man was diagnosed as having essential thrombocythemia (ET) in 1994. He had been treated with hydroxyurea (HU) for six years, and 9 years after the diagnosis of ET, he then developed acute myelomonocytic leukemia (AMMoL) following myelodysplastic syndrome (MDS). Since he suffered from ischemic heart disease, we chose the ara-C+VP-16 therapy. Two courses of the ara-C+VP-16 therapy resulted in partial remission in the bone marrow and a prolonged hematological response. This case seemed rare, since in previous reports, prognosis of ET patients developing MDS and AML was very poor and most of the patients expired within six months.

• Authors: Yuko Ishii, Akihiko Goto, Tomoko Katagiri, Keisuke Miyazawa, Kazuma Ohyashiki
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 45 Issue 11 Pg. 1211-3 (Nov 2004) ISSN: 0485-1439 [Print] Japan
• PMID: 15609690 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antimetabolites, Antineoplastic
• Antineoplastic Agents, Phytogenic
• Cytarabine
• Etoposide

Topics

• Aged
• Antimetabolites, Antineoplastic (administration & dosage)
• Antineoplastic Agents, Phytogenic (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cytarabine (administration & dosage)
• Etoposide (administration & dosage)
• Humans
• Leukemia, Myelomonocytic, Acute (drug therapy, etiology)
• Male
• Thrombocytopenia (complications)
• Treatment Outcome